# NCT00644228 (NCT00644228)

> Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00644228
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma
- Interventions: Bortezomib; Dexamethasone; Laboratory Biomarker Analysis; Lenalidomide
- Enrollment: 525
- Primary outcome: Progression-free Survival

## Commentary we found

- X threads: 13
- YouTube: 4
- Podcasts: 3
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct00644228

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00644228", "email": "<work email>"}; the inbox owner confirms by the emailed link.